The U.S. Food and Drug Administration told staff this week it cannot guarantee work space or parking spots among the hurdles ...

In Thursday's meeting, Jacqueline Corrigan-Curay, director of the FDA's Center for Drug Evaluation and Research, said plans ...

Psychedelics have the potential to treat chronic conditions such as post-traumatic stress disorder (PTSD), depression, obsessive-compulsive disorder (OCD), fibromyalgia, and various behavioral ...

At the recent CBER agency workshop on cell therapies and tissue-based products, a few surprising ideas discussed could have ...

Patrizia Cavazzoni was formerly director of the FDA’s Center for Drug Evaluation and Research (CDER) from 2020 until January, when she resigned just ahead of President Trump’s return to office.

most notably Texas Children’s Hospital and The University of Texas MD Anderson Cancer Center. The CDD bridges the gap between academic research and pharmaceutical discovery and provides researchers ...

Cavazzoni joined the FDA in 2018 and became director of its Center for Drug Evaluation and Research in 2021, where she led the regulatory and policy decisions on prescription and over-the-counter ...

and Reproductive Medicine at FDA's Center for Drug Evaluation and Research, said in a statement. Notably, the bile acid product is not new to the U.S. market. Chenodeoxycholic acid was approved in ...

With all the uncertainties surrounding the Food and Drug Administration under ... The FDA’s Center for Biologics Evaluation and Research (CBER) ran the meeting, which also had some encouraging ...